Cargando…
A Narrative Review of COVID-19 Vaccines
The COVID-19 pandemic has shaken the world since early 2020 and its health, social, economic, and societal negative impacts at the global scale have been catastrophic. Since the early days of the pandemic, development of safe and effective vaccines was judged to be the best possible tool to minimize...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779282/ https://www.ncbi.nlm.nih.gov/pubmed/35062723 http://dx.doi.org/10.3390/vaccines10010062 |
_version_ | 1784637537212432384 |
---|---|
author | Eroglu, Barbaros Nuwarda, Rina Fajri Ramzan, Iqbal Kayser, Veysel |
author_facet | Eroglu, Barbaros Nuwarda, Rina Fajri Ramzan, Iqbal Kayser, Veysel |
author_sort | Eroglu, Barbaros |
collection | PubMed |
description | The COVID-19 pandemic has shaken the world since early 2020 and its health, social, economic, and societal negative impacts at the global scale have been catastrophic. Since the early days of the pandemic, development of safe and effective vaccines was judged to be the best possible tool to minimize the effects of this pandemic. Drastic public health measures were put into place to stop the spread of the virus, with the hope that vaccines would be available soon. Thanks to the extraordinary commitments of many organizations and individuals from around the globe and the collaborative effort of many international scientists, vaccines against COVID-19 received regulatory approval for emergency human use in many jurisdictions in less than a year after the identification of the viral sequence. Several of these vaccines have been in use for some time; however, the pandemic is still ongoing and likely to persist for the foreseeable future. This is due to many reasons including reduced compliance with public health restrictions, limited vaccine manufacturing/distribution capacity, high rates of vaccine hesitancy, and the emergence of new variants with the capacity to spread more easily and to evade current vaccines. Here we discuss the discovery and availability of COVID-19 vaccines and evolving issues around mass vaccination programs. |
format | Online Article Text |
id | pubmed-8779282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87792822022-01-22 A Narrative Review of COVID-19 Vaccines Eroglu, Barbaros Nuwarda, Rina Fajri Ramzan, Iqbal Kayser, Veysel Vaccines (Basel) Review The COVID-19 pandemic has shaken the world since early 2020 and its health, social, economic, and societal negative impacts at the global scale have been catastrophic. Since the early days of the pandemic, development of safe and effective vaccines was judged to be the best possible tool to minimize the effects of this pandemic. Drastic public health measures were put into place to stop the spread of the virus, with the hope that vaccines would be available soon. Thanks to the extraordinary commitments of many organizations and individuals from around the globe and the collaborative effort of many international scientists, vaccines against COVID-19 received regulatory approval for emergency human use in many jurisdictions in less than a year after the identification of the viral sequence. Several of these vaccines have been in use for some time; however, the pandemic is still ongoing and likely to persist for the foreseeable future. This is due to many reasons including reduced compliance with public health restrictions, limited vaccine manufacturing/distribution capacity, high rates of vaccine hesitancy, and the emergence of new variants with the capacity to spread more easily and to evade current vaccines. Here we discuss the discovery and availability of COVID-19 vaccines and evolving issues around mass vaccination programs. MDPI 2021-12-31 /pmc/articles/PMC8779282/ /pubmed/35062723 http://dx.doi.org/10.3390/vaccines10010062 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Eroglu, Barbaros Nuwarda, Rina Fajri Ramzan, Iqbal Kayser, Veysel A Narrative Review of COVID-19 Vaccines |
title | A Narrative Review of COVID-19 Vaccines |
title_full | A Narrative Review of COVID-19 Vaccines |
title_fullStr | A Narrative Review of COVID-19 Vaccines |
title_full_unstemmed | A Narrative Review of COVID-19 Vaccines |
title_short | A Narrative Review of COVID-19 Vaccines |
title_sort | narrative review of covid-19 vaccines |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779282/ https://www.ncbi.nlm.nih.gov/pubmed/35062723 http://dx.doi.org/10.3390/vaccines10010062 |
work_keys_str_mv | AT eroglubarbaros anarrativereviewofcovid19vaccines AT nuwardarinafajri anarrativereviewofcovid19vaccines AT ramzaniqbal anarrativereviewofcovid19vaccines AT kayserveysel anarrativereviewofcovid19vaccines AT eroglubarbaros narrativereviewofcovid19vaccines AT nuwardarinafajri narrativereviewofcovid19vaccines AT ramzaniqbal narrativereviewofcovid19vaccines AT kayserveysel narrativereviewofcovid19vaccines |